Presentation is loading. Please wait.

Presentation is loading. Please wait.

Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center.

Published byRandolph Cameron Modified over 9 years ago

Similar presentations

Presentation on theme: "Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center."— Presentation transcript:

1 Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center for Drug Evaluation and Research Food and Drug Administration Clinical Pharmacology Subcommittee October 18, 2006 Rockville, Maryland

2 Outline Exposure to tamoxifen and metabolites after administration of tamoxifen Exposure to tamoxifen and metabolites after administration of tamoxifen Pharmacology of tamoxifen, endoxifen, and other metabolites Pharmacology of tamoxifen, endoxifen, and other metabolites CYP2D6-mediated metabolism of tamoxifen and formation of endoxifen in vitro CYP2D6-mediated metabolism of tamoxifen and formation of endoxifen in vitro Role of CYP2D6 in formation of endoxifen in vivo Role of CYP2D6 in formation of endoxifen in vivo –CYP2D6 genotype –Strong Inhibitors of CYP2D6

3 Case Report 45 year-old woman presented with intense, intolerable hot flashes after being prescribed 20 mg of tamoxifen per day for a week. 45 year-old woman presented with intense, intolerable hot flashes after being prescribed 20 mg of tamoxifen per day for a week. Placed on 10 mg per day of paroxetine for depression Placed on 10 mg per day of paroxetine for depression Resolution of hot flashes within a week Resolution of hot flashes within a week Hot flashes resumed when taken off paroxetine Hot flashes resumed when taken off paroxetine Personal Communication from David Flockhart

4 Classic Understanding of Tamoxifen Pharmacology Estradiol (E2) E2-ER ERE Tamoxifen 4OH-Tam-ER 4OH-Tam 2D6 Antagonism: Breast CNS Agonism: Bone Liver Uterus

5 Hypothesis: CYP2D6 inhibition interferes with formation of 4-OH-tamoxifen 12 women with hx of breast cancer receiving tamoxifen (20 mg/day) as adjuvant treatment for at least 4 weeks before starting the study 12 women with hx of breast cancer receiving tamoxifen (20 mg/day) as adjuvant treatment for at least 4 weeks before starting the study –History of troublesome hot flashes for which treatment with a non-hormonal agent was considered to be appropriate Blood samples collected before and after 4 weeks of co-administration of tamoxifen with 10 mg/day paroxetine Blood samples collected before and after 4 weeks of co-administration of tamoxifen with 10 mg/day paroxetine

6 Paroxetine Administration Decreased the Concentration of One Metabolite Before After 4OHTam X X As modified from Stearns et al. JNCI 2003: 95:1758-1764. X X Separated, purified, identified and synthesized metabolite X: 4-hydroxy-N-desmethyl tamoxifen (Endoxifen) Concentration of endoxifen is ~ 10x > 4-OH-tamoxifen

7 Paroxetine and CYP2D6 genotype change the plasma concentrations of endoxifen (but not of tamoxifen, N-desmethyl, or 4-hydroxy-tamoxifen ) from Stearns et al. JNCI 2003: 95:1758-1764, as communicated by D. Flockhart

8 What is the relative pharmacological activity of tamoxifen and its metabolites? Tamoxifen and N-desmethyl-tamoxifen have similar pharmacologic activity 1 Tamoxifen and N-desmethyl-tamoxifen have similar pharmacologic activity 1 4-OH-tamoxifen is 30-100 times more potent as antiestrogen than tamoxifen 2 4-OH-tamoxifen is 30-100 times more potent as antiestrogen than tamoxifen 2 Endoxifen is equipotent to 4-OH-tamoxifen (and has 5-10x higher concentration) 1 Nolvadex (Tamoxifen Citrate) label. 9-27-2005. Wilmington, Delaware, AstraZeneca Pharmaceuticals LP. 2 Coezy E, Borgna JL, and Rochefort H. Cancer Res. 1982;4:317-23.

9 4-OH-Tamoxifen and 4-OH-N-Des-Tamoxifen have equal affinities for Estrogen Receptor α Johnson MD, et al. Breast Cancer Research and Treatment, 2004; 85:151-159.

10 Endoxifen and 4-OH-Tamoxifen are Equipotent as Inhibitors of Estrogen Stimulated Cell Proliferation in MCF7 Cells Stearns V et al. JNCI 2003; 95:1758-64

11 In vitro studies suggest N-desmethyl-TAM accounts for majority of primary TAM oxidation Desta et al. JPET 2004; 310:1062-1075

12 Desta et al. JPET 2004; 310:1062-1075 and personal communication from D. Flockhart CYP2D6 is the principal route of metabolism to Endoxifen

13 modified from Stearns et al. JNCI 2003: 95:1758-1764 CYP3A4

14 Pharmacogenetics of CYP2D6 (debriosquine metabolic ratio) Alvan G, Bertilsson L, Dahl M.-L., Ingleman-Sundber M, and Sjöqvist F. Drug Metab Sip 2001; 29:580-585

15 CYP2D6 Genotype, CYP2D6 Inhibitors, and Tamoxifen Exposure 80 pre- and postmenopausal women with newly diagnosed breast cancer starting tamoxifen (20 mg/day) as adjuvant therapy 80 pre- and postmenopausal women with newly diagnosed breast cancer starting tamoxifen (20 mg/day) as adjuvant therapy Blood samples for determination of tamoxifen and metabolites in plasma Blood samples for determination of tamoxifen and metabolites in plasma Genotype functional and variant alleles of: Genotype functional and variant alleles of: –CYP3A5 (*1, *3) –CYP2D6 (*1, *3, *4, *5, *6) –CYP2C9 (*1, *2, *3) –SULT1A1 (*1,*2) No statistically significant associations of candidate genotypes with tamoxifen or metabolite exposure except for CYP2D6 No statistically significant associations of candidate genotypes with tamoxifen or metabolite exposure except for CYP2D6 Jin Y et al. JNCI 2005; 97:30-39

16 CYP2D6 Vt/Vt genotype has decreased endoxifen exposure

17 CYP2D6 inhibitors decrease endoxifen exposure Strong: paroxetine, fluoxetine Weak: amiodarone, sertraline Other: metoclopramide, citalopram Jin Y et al. JNCI 2005; 97:30-39

18 Commonly used antidepressants and endoxifen concentrations Jin Y et al. JNCI 2005; 97:30-39 CYP2D6 inhibitor: Strong: Paroxetine Weak: Sertraline

19 Effect of CYP2D6 genotype on endoxifen/NDM ratio and endoxifen plasma concentration (n=158) *, P < 0.001 *, P < 0.01 Borges S et al. Clin Pharmacol Ther 2006; 80:61-74.

20 Conclusions Endoxifen is an active metabolite of tamoxifen, present in patients at 5-10 x greater concentration than 4-OH-tamoxifen Endoxifen is an active metabolite of tamoxifen, present in patients at 5-10 x greater concentration than 4-OH-tamoxifen In vitro studies demonstrate the primary role of CYP2D6 in the formation of endoxifen. In vitro studies demonstrate the primary role of CYP2D6 in the formation of endoxifen. Potent inhibitors of CYP2D6 reduce endoxifen concentrations in patients taking tamoxifen Potent inhibitors of CYP2D6 reduce endoxifen concentrations in patients taking tamoxifen CYP2D6 genotype correlates with endoxifen concentrations in patients taking tamoxifen CYP2D6 genotype correlates with endoxifen concentrations in patients taking tamoxifen

21 Acknowledgements Larry Lesko, PhD Larry Lesko, PhD Shiew Mei Huang, PhD Shiew Mei Huang, PhD NAM Atiqur Rahman, PhD NAM Atiqur Rahman, PhD Felix Frueh, PhD Felix Frueh, PhD Myong-Jin Kim, PharmD Myong-Jin Kim, PharmD Todd Skaar, PhD Todd Skaar, PhD David Flockhart, MD, PhD David Flockhart, MD, PhD

Download ppt "Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center."

Similar presentations

© 2013 North American Menopause Society. Menopause. 2013;20(9):886-904 Key points from the 2013 Position Statement of The North American Menopause Society.

© 2013 North American Menopause Society. Menopause. 2013;20(9): Key points from the 2013 Position Statement of The North American Menopause Society.
Imaging to Guide Early Drug Trials David A. Mankoff, MD, PhD Seattle Cancer Care Alliance University of Washington Seattle, WA work supported by NIH Grants.

Imaging to Guide Early Drug Trials David A. Mankoff, MD, PhD Seattle Cancer Care Alliance University of Washington Seattle, WA work supported by NIH Grants.
Breast cancer chemoprevention in the high-risk patient

Breast cancer chemoprevention in the high-risk patient
Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.

Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.

FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.
1 How New Insights into Pharmacogenomics Lead to Revisions of Product Labels Shiew-Mei Huang, Ph.D. Deputy Director for Science Office of Clinical Pharmacology.

1 How New Insights into Pharmacogenomics Lead to Revisions of Product Labels Shiew-Mei Huang, Ph.D. Deputy Director for Science Office of Clinical Pharmacology.
Pharmacogenetics and the Management of Breast Cancer: Optimization of Tamoxifen Therapy Mark E. Sobel, M.D., Ph.D. Executive Officer American Society for.

Pharmacogenetics and the Management of Breast Cancer: Optimization of Tamoxifen Therapy Mark E. Sobel, M.D., Ph.D. Executive Officer American Society for.
Determining Estrogenicity of a Cytochrome P450- dependent metabolite of 3,3’-diindolylmethane (DIM) Rachel O’Neal Susan Tilton Dr. David Williams Marine.

Determining Estrogenicity of a Cytochrome P450- dependent metabolite of 3,3’-diindolylmethane (DIM) Rachel O’Neal Susan Tilton Dr. David Williams Marine.
Hepatic generation of active metabolite Pharmacogenetics of Cardiovascular Antithrombotic Therapy CYP = cytochrome P450. GP = glycoprotein. MDR = multidrug.

Hepatic generation of active metabolite Pharmacogenetics of Cardiovascular Antithrombotic Therapy CYP = cytochrome P450. GP = glycoprotein. MDR = multidrug.
Robertson JFR et al. J Clin Oncol 2009;27(27):

Robertson JFR et al. J Clin Oncol 2009;27(27):
Sublingual Buprenorphine and Pain

Sublingual Buprenorphine and Pain
Mechanistic PBPK as an aid in identifying the size of covariate effects and design of POPPK studies: An example focusing on haematocrit as a determinant.

Mechanistic PBPK as an aid in identifying the size of covariate effects and design of POPPK studies: An example focusing on haematocrit as a determinant.
Clinical implications of pharmacogenetic research S:t Petersburg April 4, 2008 Professor Leif Bertilsson Dept. of Clinical Pharmacology Karolinska University.

Clinical implications of pharmacogenetic research S:t Petersburg April 4, 2008 Professor Leif Bertilsson Dept. of Clinical Pharmacology Karolinska University.
Ibrance® - Palbociclib

Ibrance® - Palbociclib
Gastrointestinal Drugs Advisory Committee Meeting March 6, 2003 Drug Interactions of Aprepitant Venkat Jarugula, Ph.D. Clinical Pharmacology and Biopharmaceutics.

Gastrointestinal Drugs Advisory Committee Meeting March 6, 2003 Drug Interactions of Aprepitant Venkat Jarugula, Ph.D. Clinical Pharmacology and Biopharmaceutics.
Tamoxifen Pharmacogenetics and Prediction of Breast Cancer Relapse After Administration of Tamoxifen Matthew P. Goetz, MD Assistant Professor of Oncology.

Tamoxifen Pharmacogenetics and Prediction of Breast Cancer Relapse After Administration of Tamoxifen Matthew P. Goetz, MD Assistant Professor of Oncology.
CYP2C8 and Drug Interactions

CYP2C8 and Drug Interactions
Pharmacogenetics of Tamoxifen An FDA Perspective

Pharmacogenetics of Tamoxifen An FDA Perspective
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug metabolite ratios in blood Levo et al. Forensic Science International.

Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug metabolite ratios in blood Levo et al. Forensic Science International.

Similar presentations

Ads by Google